Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lapaquistat acetate + current lipid-lowering treatment
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lapaquistat acetate (TAK-475) is a small molecule inhibitor of squalene synthase (farnesyl-diphosphate farnesyltransferase), an enzyme that catalyzes the conversion of farnesyl diphosphate to squalene in the cholesterol biosynthesis pathway. This step occurs downstream of the HMG-CoA reductase step targeted by statins. Developed by Takeda, lapaquistat acetate was investigated as a treatment for hypercholesterolemia and dyslipidemia, including a specific Phase 3 study where it was co-administered with existing (current) lipid-lowering therapies—such as statins and ezetimibe—in patients with homozygous familial hypercholesterolemia (HoFH). Although it demonstrated significant LDL cholesterol reduction in clinical trials, Takeda discontinued its development in March 2008 due to hepatic safety concerns, specifically elevations in liver enzymes such as alanine aminotransferase (ALT).
- Other names
- Current lipid-lowering treatment-Takeda-homozygous familial hypercholesterolemialapaquistat acetateTAK-475 + current lipid-lowering treatment
02
Targets
FDFT1 (Squalene synthase)
Beyond the preview
Go deeper on lapaquistat acetate + current lipid-lowering treatment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lapaquistat acetate + current lipid-lowering treatment.